Rapid and sensitive method for simultaneous determination of first-line anti-tuberculosis drugs in human plasma by HPLC-MS/MS: Application to therapeutic drug monitoring.

[1]  Hongmei Yang,et al.  Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection , 2016, Antimicrobial Agents and Chemotherapy.

[2]  A. Cohen,et al.  Simultaneous quantification of isoniazid, rifampicin, ethambutol and pyrazinamide by liquid chromatography/tandem mass spectrometry , 2016, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[3]  D. Kibuule,et al.  Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring , 2016, European Journal of Clinical Pharmacology.

[4]  P. Donald,et al.  Antituberculosis drugs in children , 2015, Clinical pharmacology and therapeutics.

[5]  Jae-Gook Shin,et al.  Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography-electrospray ionization-tandem mass spectrometry. , 2015, Journal of pharmaceutical and biomedical analysis.

[6]  L. Lee,et al.  Development and validation of liquid chromatography tandem mass spectrometry method for simultaneous quantification of first line tuberculosis drugs and metabolites in human plasma and its application in clinical study. , 2015, Journal of pharmaceutical and biomedical analysis.

[7]  S. Heysell,et al.  Understanding pharmacokinetics to improve tuberculosis treatment outcome , 2014, Expert opinion on drug metabolism & toxicology.

[8]  E. Houpt,et al.  Early Therapeutic Drug Monitoring for Isoniazid and Rifampin among Diabetics with Newly Diagnosed Tuberculosis in Virginia, USA , 2013, Tuberculosis research and treatment.

[9]  S. Song,et al.  Method for simultaneous analysis of nine second-line anti-tuberculosis drugs using UPLC-MS/MS. , 2013, The Journal of antimicrobial chemotherapy.

[10]  B. Greijdanus,et al.  Troubleshooting carry-over of LC-MS/MS method for rifampicin, clarithromycin and metabolites in human plasma. , 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[11]  J. Fitzgerald,et al.  Therapeutic drug monitoring in the treatment of tuberculosis: a retrospective analysis. , 2013, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[12]  S. Mcdougall,et al.  Analytical bias between species caused by matrix effects in quantitative analysis of a small-molecule pharmaceutical candidate in plasma. , 2012, Bioanalysis.

[13]  M. Boeree,et al.  Therapeutic drug monitoring in the treatment of tuberculosis patients. , 2012, Pulmonary pharmacology & therapeutics.

[14]  J. Pasipanodya,et al.  Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. , 2011, The Journal of infectious diseases.

[15]  D. Menzies,et al.  Therapeutic drug monitoring in the treatment of active tuberculosis. , 2011, Canadian respiratory journal.

[16]  S. Swaminathan,et al.  Pharmacokinetics of Anti-tuberculosis Drugs in Children , 2011, Indian journal of pediatrics.

[17]  E. Houpt,et al.  Therapeutic Drug Monitoring for Slow Response to Tuberculosis Treatment in a State Control Program, Virginia, USA , 2010, Emerging infectious diseases.

[18]  Z. Gong,et al.  A rapid and robust liquid chromatography/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs--ethambutol and pyrazinamide in human plasma. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[19]  S. Song,et al.  Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. , 2007, Rapid communications in mass spectrometry : RCM.

[20]  B. Alisjahbana,et al.  Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  D. Menzies,et al.  Adverse reactions to first-line antituberculosis drugs , 2006, Expert opinion on drug safety.

[22]  M. Eichelbaum,et al.  Pharmacokinetics of oral and intravenous rifampicin during chronic administration , 1985, Klinische Wochenschrift.

[23]  R. Ridzon,et al.  Use of therapeutic drug monitoring for multidrug-resistant tuberculosis patients. , 2004, Chest.

[24]  T. Hodge,et al.  Low isoniazid concentrations and outcome of tuberculosis treatment with once-weekly isoniazid and rifapentine. , 2003, American journal of respiratory and critical care medicine.

[25]  D. Marriott,et al.  Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid , 2003, Internal medicine journal.

[26]  F. Fountain,et al.  Utility of rifampin blood levels in the treatment and follow-up of active pulmonary tuberculosis in patients who were slow to respond to routine directly observed therapy. , 2001, Chest.

[27]  B. Blomberg,et al.  The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. , 2001, Bulletin of the World Health Organization.

[28]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[29]  M. Eichelbaum,et al.  Influence of the enzyme induction by rifampicin on its presystemic metabolism. , 1987, Pharmacology & therapeutics.